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INTRODUCTION
Osmotic Demyelination Syndrome (ODS) occurs following rapid 
overcorrection of hyponatremia.1 It is characterized by destruction 
of neuronal myelin sheaths in either the central area of the pons or in 
other susceptible areas causing severe irreversible neurologic defi-
cits. Methods described in the literature suggested varying sodium 
correction rates which lead to different definitions of overcorrection 
of hyponatremia.2 The incidence of ODS consequently would be 
expected to increase. However, no general consensus exists regarding 
the optimal treatment regimen for this disease. Nevertheless, evi-
dence-based management is essential for those who are diagnosed. 
We present a case of ODS treated with plasmapheresis (PP), intrave-
nous immunoglobulins (IVIG), and intravenous methylprednisolone 
with significant recovery of neurologic function.
CASE REPORT
A 49-year-old male with a history of peptic ulcer disease and newly 
diagnosed hypertension was transferred to our facility for manage-
ment of acute neurological deficits. He was also an alcoholic and had 
been drinking eight beers daily for the past 10 years. Three weeks 
prior to arrival to our hospital, the patient’s primary care provider 
(PCP) started him on hydrochlorothiazide for new-onset hyperten-
sion. A renal panel was drawn during the office visit and revealed a 
sodium level of 135 mEq/L. Two weeks following the initiation of the 
thiazide drug, a renal panel revealed a sodium level of 128 mEq/L. 
Two days later, he started having acute behavioral changes which 
prompted his wife to take him to the nearest hospital in their vicinity. 
The patient was admitted to the peripheral hospital for severe 
symptomatic hypovolemic hyponatremia with a sodium level of 102 
mEq/L. Per the transfer notes, he was treated with three boluses of 
1 liter of normal saline followed by 900 ml of hypertonic saline (3%) 
at a rate of 100 ml/hour, which increased his sodium level to 140 
mEq/L. The patient did not exhibit any neurologic deficits during the 
admission and upon discharge. He was sent home the following day 
with instructions to discontinue hydrochlorothiazide. 
Follow-up laboratory testing were obtained at the PCP’s clinic the 
day he was discharged and revealed a sodium level of 138 mEq/L. 
However, the patient’s wife noticed that her husband started devel-
oping bilateral tremors, rigidity, and dysarthria. She took him back to 
the facility from which he was discharged for evaluation. He was re-
admitted there for treatment of sodium overcorrection. He was given 
5% dextrose in 0.45% normal saline and 2 mcg of desmopressin, then 
transferred to our hospital for a higher level of care. 
Upon arrival to our facility, his sodium level was 141 mEq/L. His 
physical examination was remarkable for lethargy, diaphoresis, and 
decorticate posture. He was arousable to voice commands and was 
aphasic. His pupils were pinpoint, equal, and reactive. Bilateral upper 
and lower extremities were stiff and tremulous, while reflexes were 
difficult to assess. Magnetic resonance imaging (MRI) of the brain 
revealed pathologic diffusion restriction within the central pons with 
hyperintense signals in the basal ganglia (Figure 1). Electroencepha-
logram (EEG) did not show any epileptiform discharges.
The patient’s hyponatremia was corrected from 102 to 140 mEq/L 
within less than 24 hours during his first admission. He then started 
developing acute neurological symptoms concerning for brainstem 
dysfunction. MRI of his brain ruled out stroke and revealed features 
pathognomonic of central pontine myelinolysis. EEG ruled out status 
epilepticus or any seizure activity. The patient’s clinical picture was 
most consistent with osmotic demyelination syndrome.
Figure 1. Magnetic resonance imaging of the brain showing diffusion restriction 
within the pontine region sparing the descending tracts (arrows) which is typi-
cally seen in osmotic demyelination syndrome.
The nephrology team initiated 2 mcg of desmopressin every six 
hours and 5% dextrose in water with a goal to lower sodium to 120 
mEq at a rate of 6 - 8 mEq per day. Treatment options and prognosis 
were discussed with the patient’s wife. PP, IVIG, and steroids were 
initiated in an attempt to recover his neurologic function as much as 
possible. He received plasmapheresis every other day for a total of six 
treatments. He was given 125 mg of intravenous methylprednisolone 
every eight hours for three days followed by dose tapering and 25 g 
of IVIG daily for five days. The neurology team started levetirace-
tam 500 mg twice a day for seizure prophylaxis. Sodium level was 
maintained around 120 mEq during the first five days and gradually 
increased by 4 mEq daily thereafter. 
During the course of his admission, he required intubation due to 
his altered mental status and inability to protect his airways. Follow-
ing extubation, he required a percutaneous endoscopic gastrostomy 
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KANSAS JOURNAL of  M E D I C I N E(PEG) tube for feeding. He worked daily with a multidisciplinary 
team, including speech, physical, and occupational therapy. Eleven 
weeks following admission, the patient was 30% weight-bearing and 
was able to speak in short sentences. The PEG tube was removed 
and he was able to swallow pureed food and thickened liquids. He 
was able to use utensils for feeding, comb his hair, and wash his face. 
He required some assistance during bathing and dressing. He was 
discharged to a skilled nursing facility for inpatient rehabilitation 
services. Six months following his discharge, he was able to walk 
using a cane, perform activities of daily living without assistance, and 
regained 60% of his strength.
DISCUSSION
ODS is characterized by severe irreversible neurological deficits. 
The spectrum of symptoms is wide and affected individuals can 
exhibit one or a combination of encephalopathy, extrapyramidal 
symptoms, seizures, dystonia, gaze palsy, quadriparesis, dysarthria, 
dysphagia, and/or locked-in syndrome.3,4 The most common incit-
ing event is rapid correction of hyponatremia. Additional risk factors 
include concurrent electrolyte imbalances, a sodium level less than 
105 mEq/L, chronic alcoholism, diuretics use, liver transplant, mal-
nutrition, and endocrinopathies.3 
Thiazide diuretics, in particular, are known to cause serious inter-
actions when mixed with alcohol.5 This combination was probably 
the main culprit behind his profound hyponatremia. Prognosis is very 
poor and small case studies have shown that a third of the patients 
die after one year.3,6 Among those that survive, the rate and degree of 
recovery of neurologic function is unpredictable. The pathogenesis of 
ODS is poorly understood making its management challenging and 
uncertain. During the treatment of hyponatremia, the serum osmo-
lality increases with the increasing sodium concentration. Water 
shifts out of the brain cells to equilibrate between intracellular and 
extracellular solute concentration. Organic osmolytes are neces-
sary for the protection of astrocytes and oligodendrocytes. When 
shrinking of glial cells occurs at a faster rate than repletion of organic 
osmolytes, most commonly during rapid correction of hyponatremia, 
programmed cell death is activated in these myelin producing cells 
leading to disruption of the blood brain barrier and release of inflam-
matory cytokines.7,8
In an attempt to minimize the incidence of ODS, the American 
Society of Nephrology has set forth guidelines regarding therapeutic 
goals and limits for the management of hyponatremia.9 The recom-
mended rate of sodium correction in acute hyponatremia is 4 to 6 
mEq/L within the first two hours, with a limit of 10 mEq/L within 24 
hours and 8 mEq/L per day thereafter. For chronic hyponatremia, 
the recommended rate is 4 to 6 mEq/L within the first 12 hours and 
8 mEq/L per day afterwards.9 However, Woodfine et al.2 showed in 
their cohort study that ODS may occur in patients regardless of the 
rate of sodium correction. 
Multiple treatment options have been proposed for ODS includ-
ing intravenous methylprednisolone, IVIG, and PP. However, these 
recommendations are based on small case series. Atchaneeyasakul 
et al.10 theorized that PP reduces the myelinotoxic products released 
following the osmotic stress. Five cases treated with PP resulted in 
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near complete recovery of neurological symptoms.11-13 Murase et 
al.8 demonstrated that ODS can have an autoimmune component 
as well, antibodies are released following the osmotic insult into the 
circulation. Six patients had significant recovery following treatment 
with IVIG.14-17 Treatment with both PP and IVIG has been trialed as 
well with significant improvement in four patients.10,18,19 The use of 
intravenous methylprednisolone has been described as well, however, 
further studies are needed to establish the true efficacy of the use of 
steroids in this setting.3,20 
Case reports usually describe regimens with successful outcomes. 
Patients who did not benefit from specific treatments are not docu-
mented in the literature, making it difficult to evaluate the efficacy 
and success rate associated with every treatment available. No clini-
cal trials have been initiated for the treatment of ODS. In an attempt 
to provide our patient with the highest chance of recovery possible, 
he was treated with PP, IVIG, and steroids. Recovery was achieved 
gradually with the support of a multidisciplinary team (physical, 
occupational, and speech therapy).
The aim of our case report was to provide data regarding the 
outcome following triple therapy and to invite more physicians to 
report positive and negative progress seen in patients treated as such. 
To the best of our knowledge, this is the first case of ODS treated with 
PP, IVIG, and intravenous methylprednisolone concurrently. 
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